Lupin signs exclusive European deal with Visus for Yuvezi
Lupin Limited has secured exclusive rights to commercialize Yuvezi, a presbyopia treatment, in the EU, UK, Switzerland, Norway, and Iceland through a deal with Visus Therapeutics. The agreement involves a €20 million strategic investment and up to €55 million in milestones, totaling €75 million in potential payments.
*this image is generated using AI for illustrative purposes only.
Lupin Limited has entered into an exclusive licensing agreement with Visus Therapeutics for Yuvezi (YuveziTM) covering the European market. The deal carries total potential payments of up to €75 million, structured as a combination of strategic funds and milestone payouts.
Deal highlights
The key parameters of the agreement are outlined below:
| Parameter: | Details |
|---|---|
| Partner: | Visus Therapeutics |
| Product: | Yuvezi (YuveziTM) |
| Territory: | Europe, UK, Switzerland, Norway, Iceland |
| Deal structure: | Exclusive licensing agreement |
| Total potential payments: | Up to €75 million |
| Payment components: | Strategic funds and milestone payouts |
The agreement grants Lupin exclusive rights to commercialise Yuvezi across Europe, with the total consideration contingent on the achievement of defined milestones in addition to the upfront strategic component.
Expanded territory and structure
The agreement, signed on August 20, 2026, expands the licensed territories beyond the initial European scope to include the United Kingdom, Switzerland, Norway, and Iceland. VISUfarma B.V., a wholly owned subsidiary of Lupin, holds the exclusive rights to undertake regulatory activities, commercialization, marketing, promotion, distribution, and sale of Yuvezi in these regions.
The financial structure comprises two main components:
- A €20 million strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument.
- Up to €55 million in regulatory and commercial milestone payments.
Additionally, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the licensed territories.
Strategic rationale
This partnership strengthens Lupin's ophthalmology portfolio and expands its Specialty Business presence. Yuvezi is indicated for the treatment of presbyopia in adults. The addition of this asset supports Lupin's strategy for expanding its specialty care business through innovative therapies that address significant unmet patient needs in the aging eye segment.
Historical Stock Returns for Lupin
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.01% | -2.16% | -11.16% | -0.79% | +13.48% | +137.62% |
How might the €20 million SAFE investment impact Visus Therapeutics' valuation and future fundraising capabilities?
What are the primary competitive threats Yuvezi faces in the European presbyopia treatment market upon launch?
How does this acquisition align with Lupin's broader strategy to shift revenue mix from generics to specialty pharmaceuticals?
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
